Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial.

Abstract

BACKGROUND Atypical antipsychotics may be useful in treating aggression associated with autistic spectrum disorder (ASD). We evaluated the effectiveness of low-dose quetiapine treatment in ASD adolescent patients with aggressive behavior. METHOD Eleven adolescent patients (8 boys and 3 girls) diagnosed with ASD, aged 13 to 17 years, were treated with quetiapine in an open-label study over an 8-week period. The severity of ASD, aggressive behavior, and sleep disturbances were assessed using the Clinical Global Impression-Severity (CGI-S), Overt Aggression Scale, and Child Sleep Habits Questionnaire, respectively. RESULTS Nonsignificant changes were obtained in autistic behavior after quetiapine treatment (CGI-S: 4.0 ± 0.6 vs CGI-S after: 3.1 ± 1.1; 2-tailed paired t = 1.93; df = 10; P = 0.08). Severity of aggressive behavior decreased significantly after quetiapine treatment (Overt Aggression Scale: 2.1 ± 0.94 vs 1.3 ± 0.64, respectively; 2-tailed paired t = 2.37; df =10; P = 0.028). Sleep disturbances improved significantly (Child Sleep Habits Questionnaire: 49.0 ± 12 vs 44.1 ± 9.6; 2-tailed paired t = 2.98; df =10; P = 0.014) and a positive correlation was found between the improvements in aggression and sleep (Spearman correlation: r = 0.43; N = 11; P = 0.013). Quetiapine was well tolerated. CONCLUSION Short-term low-dose quetiapine treatment may reduce aggression levels and improve sleep quality in adolescents with ASD.

DOI: 10.1097/WNF.0b013e31823349ac

Statistics

0500100020132014201520162017
Citations per Year

335 Citations

Semantic Scholar estimates that this publication has 335 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Golubchik2011LowdoseQF, title={Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial.}, author={Pavel Golubchik and Jonathan M Sever and Abraham Weizman}, journal={Clinical neuropharmacology}, year={2011}, volume={34 6}, pages={216-9} }